Bleximenib clinical trials
Also written JNJ-75276617.
How each study uses bleximenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the bleximenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2021 | 1 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
Janssen Research & Development, LLC (4) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · Beat AML, LLC (1)
Often tested with
Tested in the same studies.
Samalizumab (1) · BI 836858 (1) · Cytarabine (1) · Azacitidine (1) · Enasidenib (1) · Entospletinib (1) · Pevonedistat (1) · Ivosidenib (1)
Studies
Open first, then newest update. How each study uses bleximenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)RecruitingPhase 3Stichting Hemato-Oncologie voor Volwassenen NederlandNCT07223814Written as Bleximenib
- A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)RecruitingPhase 1/2Janssen Research & Development, LLCNCT04811560Written as Bleximenib
- A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)RecruitingPhase 3Janssen Research & Development, LLCNCT06852222Written as Bleximenib
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingPhase 2/3Beat AML, LLCNCT03013998Written as Bleximenib (BAML-16-001-S25/HO181)
- A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute LeukemiaCompletedPhase 1Janssen Research & Development, LLCNCT07295951Written as 14C-bleximenib
- A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute LeukemiasWithdrawnPhase 1Janssen Research & Development, LLCNCT05521087Written as JNJ-75276617
Given beside what is tested · 1 — bleximenib is usual care or a partner of the new treatment
Codes
What other systems call bleximenib · ClinicalTrials.gg INT016321
- UNII (FDA) DCN5WEN78TBLEXIMENIBConfirmed FDA, Wikidata
- Wikidata Q136419239bleximenibConfirmed FDA, Wikidata
- NCI Thesaurus C203103BleximenibOne source FDA
- DrugBank DB19328One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DCN5WEN78T | BLEXIMENIB | Confirmed FDA, Wikidata |
| Wikidata | Q136419239 | bleximenib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C203103 | Bleximenib | One source FDA |
| DrugBank | DB19328 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.